Therapeutic molecular phenotype of β-blocker-associated reverse-remodeling in nonischemic dilated cardiomyopathy

Circulation: Cardiovascular Genetics

Volumn 8, Issue 2, 2015, Pages 270-283

  Kao, David P ^a   Lowes, Brian D ^b   Gilbert, Edward M ^c   Minobe, Wayne ^a   Epperson, L Elaine ^a   Meyer, Leslie K ^a   Ferguson, Debra A ^a   Volkman, Ann Kirkpatrick ^c   Zolty, Ronald ^d   Borg, C Douglas ^e   Quaife, Robert A ^a   Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e Heart Clinic Arkansas   (United States)

Author keywords

Beta adrenergic blocking agents; Cardiomyopathy; Dilated; Gene expression; Myocardial remodeling; Myocardium; Ventricular

Indexed keywords

ACTA1 PROTEIN; ACTC1 PROTEIN; ADRB1 PROTEIN; ALPHA 1A ADRENERGIC RECEPTOR; ATRIAL NATRIURETIC FACTOR; BETA 1 ADRENERGIC RECEPTOR; CARVEDILOL; CSRP3 PROTEIN; CTF1 PROTEIN; DOXAZOSIN MESYLATE; GNAI2 PROTEIN; GNAS PROTEIN; HK2 PROTEIN; INTERLEUKIN 6; METOPROLOL SUCCINATE; MYL2 PROTEIN; MYOSIN HEAVY CHAIN ALPHA; NPPB PROTEIN; PDHX PROTEIN; PROTEIN; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2; SLC8A1 PROTEIN; SODIUM PROTON EXCHANGE PROTEIN 1; THYROID HORMONE; TNNC1 PROTEIN; TNNI3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MUSCLE PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; GENE EXPRESSION; GENE REGULATORY NETWORK; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE BIOPSY; HEART RATE; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN TISSUE; LUNG ARTERY PRESSURE; MALE; MICROARRAY ANALYSIS; NEW YORK HEART ASSOCIATION CLASS; NONISCHEMIC CARDIOMYOPATHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOISOTOPE VENTRICULOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; BIOSYNTHESIS; CARDIOMYOPATHY, DILATED; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; CARDIOMYOPATHY, DILATED; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MUSCLE PROTEINS; STROKE VOLUME;

EID: 84942784549     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.114.000767     Document Type: Article

References (50)

1. Maron BJ, Towbin JA, Thiene G, Antzelevitch C., Corrado D, Arnett D, et al Contemporary definitions and classification of the cardiomyopathies. Circulation. 2006; 113:1807-1816.
2. Nakao K, Minobe W, Roden R., Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest. 1997; 100:2362-2370. doi:10.1172/JCI119776.
3. Lowes BD, Gilbert EM, Abraham W.T., Minobe WA, Larrabee P, Ferguson D, et al Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002; 346:1357-1365. doi:10.1056/NEJMoa012630.
4. Lowes BD, Zolty R, Minobe W.A., Robertson AD, Leach S, Hunter L, et al Serial gene expression profiling in the intact human heart. J Heart Lung Transplant. 2006; 25: 579-588. doi:10.1016/j.healun.2006.01.006.
5. Sucharov CC, Mariner PD, Nunley K.R., Long C., Leinwand L, Bristow MR. A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am J Physiol Heart Circ Physiol. 2006; 291: H1299-H1308. doi:10.1152/ajpheart.00017.2006.
6. Dockstader K, Nunley K, Karimpour-Fard A, Medway A., Nelson P, Port JD, et al Temporal analysis of mRNA and miRNA expression in trans-genic mice overexpressing Arg- and Gly389 polymorphic variants of the β1-adrenergic receptor. Physiol Genomics. 2011; 43: 1294-1306. doi:10.1152/physiolgenomics.00067.2011.
7. Kinugawa K, Minobe WA, Wood W.M., Ridgway EC, Baxter JD, Ribeiro RC, et al Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation. 2001; 103: 1089-1094.
8. Eichhorn EJ, Bristow MR Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996; 94: 2285-2296.
9. Olsen SL, Gilbert EM, Renlund D.G., Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995; 25: 1225-1231. doi:10.1016/0735-1097(95)00012-S.
10. Hjalmarson A, Goldstein S, Fagerberg B., Wedel H, Waagstein F, Kjekshus J., et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure (MER-IT-HF). Lancet. 1999; 353: 2001-2007.
11. Kukin ML, Kalman J, Mannino M., Freudenberger R, Buchholz C, Ocampo O. Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure. Am J Cardiol. 1996; 77: 486-491.
12. Felker GM, Hu W, Hare J.M., Hruban RH, Baughman KL, Kasper EK. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine (Baltimore). 1999; 78: 270-283.
13. Iglewicz B, Hoaglin DC How to Detect and Handle Outliers. Milwaukee, WI: American Society for Quality Control; 1993:11-13.
14. Schmittgen TD, Livak KJ Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3: 1101-1108.
15. Irizarry RA, Bolstad BM, Collin F, Cope L.M., Hobbs B., Speed T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003; 31: e15.
16. Saleh S, Liakopoulos OJ, Buckberg GD The septal motor of biventricular function. Eur J Cardiothorac Surg. 2006; 29(Suppl 1): S126-S138. doi:10.1016/j.ejcts.2006.02.048.
17. Gilbert EM, Abraham WT, Olsen S, Hattler B., White M, Mealy P, et al Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996; 94: 2817-2825.
18. Turer AT, Stevens RD, Bain J.R., Muehlbauer MJ, van der Westhuizen J, Mathew JP, et al. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation. 2009; 119: 1736-1746. doi:10.1161/CIRCULATIONAHA.108.816116.
19. Sack MN, Harrington LS, Jonassen A.K., Mjøs OD, Yellon DM. Coordinate regulation of metabolic enzyme encoding genes during cardiac development and following carvedilol therapy in spontaneously hypertensive rats. Cardiovasc Drugs Ther. 2000; 14: 31-39.
20. Cheng L, Ding G, Qin Q., Xiao Y, Woods D, Chen Y.E., et al. Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem Biophys Res Commun. 2004; 313: 277-286.
21. Herron TJ, McDonald KS Small amounts of alpha-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res. 2002; 90: 1150-1152.
22. Schaub MC, Hefti MA, Zuellig R.A., Morano I. Modulation of contractility in human cardiac hypertrophy by myosin essential light chain isoforms. Cardiovasc Res. 1998; 37: 381-404.
23. Müller O.J., Lange M, Rattunde H., Lorenzen HP, Müller M, Frey N., et al. Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload. Cardiovasc Res. 2003; 59: 380-389.
24. Jiang M, Xu A, Tokmakejian S., Narayanan N. Thyroid hormone-induced overexpression of functional ryanodine receptors in the rabbit heart. Am J Physiol Heart Circ Physiol. 2000; 278: H1429-H1438.
25. Jensen BC, O'Connell TD, Simpson PC Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol. 2011; 51: 518-528. doi:10.1016/j.yjmcc.2010.11.014.
26. Mialet Perez J., Rathz DA, Petrashevskaya N.N., Hahn HS, Wagoner LE, Schwartz A, et al Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003; 9: 1300-1305. doi:10.1038/nm930.
27. Waspe LE, Ordahl CP, Simpson PC The cardiac beta-myosin heavy chain isogene is induced selectively in alpha 1-adrenergic receptor-stimulated hypertrophy of cultured rat heart myocytes. J Clin Invest. 1990; 85: 1206-1214. doi:10.1172/JCI114554.
28. Simpson PC, Long CS, Waspe L.E., Henrich CJ, Ordahl CP. Transcription of early developmental isogenes in cardiac myocyte hypertrophy. J Mol Cell Cardiol. 1989; 21 Suppl 5: 79-89.
29. Zhang Z, Liu R, Townsend P.A., Proud CG. p90(RSK)s mediate the activation of ribosomal RNA synthesis by the hypertrophic agonist phenylephrine in adult cardiomyocytes. J Mol Cell Cardiol. 2013; 59: 139-147. doi:10.1016/j.yjmcc.2013.03.006.
30. Kadambi VJ, Ponniah S, Harrer J.M., Hoit BD, Dorn GW II, Walsh RA, et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest. 1996; 97: 533-539. doi:10.1172/JCI118446.
31. Lindemann JP, Jones LR, Hathaway D.R., Henry BG, Watanabe AM. beta-Adrenergic stimulation of phospholamban phosphorylation and Ca2+ATPase activity in guinea pig ventricles. J Biol Chem. 1983; 258: 464-471.
32. Knowles JW, Esposito G, Mao L., Hagaman JR, Fox JE, Smithies O, et al Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest. 2001; 107: 975-984. doi:10.1172/JCI11273.
33. Kubanek M, Sramko M, Maluskova J., Kautznerova D, Weichet J, Lupinek P., et al. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. J Am Coll Cardiol. 2013; 61: 54-63. doi:10.1016/j.jacc.2012.07.072.
34. Taegtmeyer H, Sen S, Vela D. Return to the fetal gene program: a suggested metabolic link to gene expression in the heart. Ann N Y Acad Sci. 2010; 1188: 191-198. doi:10.1111/j.1749-6632.2009.05100.x.
35. Rajabi M, Kassiotis C, Razeghi P., Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev. 2007; 12: 331-343. doi:10.1007/s10741-007-9034-1.
36. Stein B, Bartel S, Kirchhefer U., Kokott S, Krause EG, Neumann J, et al Relation between contractile function and regulatory cardiac proteins in hypertrophied hearts. Am J Physiol. 1996; 270(6 Pt 2): H2021-H2028.
37. Reinecke H, Studer R, Vetter R., Holtz J, Drexler H. Cardiac Na+/Ca2+ exchange activity in patients with end-stage heart failure. Cardiovasc Res. 1996; 31: 48-54.
38. Milberg P, Pott C, Frommeyer G., Fink M, Ruhe M, Matsuda T., et al. Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure. Heart Rhythm. 2012; 9: 570-578. doi:10.1016/j.hrthm.2011.11.004.
39. Vanderheyden M, Mullens W, Delrue L., Goethals M, Verstreken S, Wijns W., et al. Endomyocardial upregulation of beta1 adrenoreceptor gene expression and myocardial contractile reserve following cardiac resyn-chronization therapy. J Card Fail. 2008; 14: 172-178. doi:10.1016/j.cardfail.2007.10.016.
40. Iyengar S, Haas G, Lamba S., Orsinelli DA, Babu GJ, Ferketich AK, et al Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy. J Card Fail. 2007; 13: 304-311. doi:10.1016/j.cardfail.2007.01.005.
41. Vanderheyden M, Mullens W, Delrue L., Goethals M, de Bruyne B, Wijns W, et al Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol. 2008; 51: 129-136. doi:10.1016/j. jacc.2007.07.087.
42. Heilbrunn SM, Shah P, Bristow M.R., Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989; 79: 483-490.
43. Abraham WT, Gilbert EM, Lowes B.D., Minobe WA, Larrabee P, Roden RL, et al Coordinate changes in Myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med. 2002; 8: 750-760.
44. Yasumura Y, Takemura K, Sakamoto A., Kitakaze M, Miyatake K. Changes in myocardial gene expression associated with beta-blocker therapy in patients with chronic heart failure. J Card Fail. 2003; 9: 469-474.
45. Barber RD, Harmer DW, Coleman R.A., Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics. 2005; 21: 389-395. doi:10.1152/physiolgenomics.00025.2005.
46. Vandesompele J, De Preter K, Pattyn F, Poppe B., Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3: RESEARCH0034.
47. Galandrin S, Bouvier M. Distinct signaling profiles of beta1 and beta2 ad-renergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006; 70: 1575-1584. doi:10.1124/mol.106.026716.
48. Wisler JW, DeWire SM, Whalen E.J., Violin JD, Drake MT, Ahn S, et al A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007; 104: 16657-16662. doi:10.1073/pnas.0707936104.
49. Nakaya M, Chikura S, Watari K., Mizuno N, Mochinaga K, Mangmool S., et al. Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent Signaling pathways. J Biol Chem. 2012; 287: 35669-35677. doi:10.1074/jbc.M112.357871.
50. Kao DP, Minobe W, Epperson L.E., Meyer L., Ferguson D, Zolty R, et al Comparison of changes in reverse remodeling associated myocardial gene expression between carvedilol and metoprolol in nonischemic dilated cardiomyopathy. Eur J Heart Fail. 2014; 16: 362.